Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 15/20 | 0.46 |
| ▸ | JAK2 | O60674 | 5/20 | 0.46 |
| ▸ | TYK2 | P29597 | 6/20 | 0.42 |
| ▸ | JAK3 | P52333 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20283374 | 1.00 | JAK1 (0.46) | JAK1JAK2TYK2JAK3CYP3A4 | |
| SCHEMBL23192445 | 0.88 | AXL (0.41) | JAK1JAK2TYK2JAK3CYP3A4 | |
| SCHEMBL24404372 | 0.82 | JAK3 (0.40) | JAK1JAK2TYK2JAK3CYP3A4 | |
| SCHEMBL20290071 | 0.81 | JAK1 (0.36) | JAK1JAK2TYK2JAK3CYP3A4 | |
| SCHEMBL30822865 | 0.78 | CYP2C9 (0.36) | JAK1JAK2JAK3 | |
| SCHEMBL12424590 | 0.77 | PRKCI (0.47) | JAK1JAK2TYK2JAK3AXL | |
| SCHEMBL29588119 | 0.77 | PRKCI (0.47) | JAK1JAK2TYK2JAK3AXL | |
| SCHEMBL14643309 | 0.77 | MLKL (0.41) | CYP1A2 | |
| SCHEMBL29587459 | 0.76 | JAK1 (0.33) | JAK1JAK2TYK2JAK3CYP3A4 | |
| SCHEMBL24642274 | 0.75 | JAK1 (0.45) | JAK1JAK2TYK2JAK3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787807-B2 | Small molecule inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-17 | — | — | US | disclosed |
| WO-2023115327-A1 | PYRIDO RING COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATION | 中国药科大学 | 2023-06-29 | — | — | WO | disclosed |
| US-20210340144-A1 | SMALL MOLECULE INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | disclosed |
| WO-2013007765-A1 | FUSED TRICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF JANUS KINASES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2011086053-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787807-B2 | Small molecule inhibitors of the JAK family of kinases | JAK2, JAK1, JAK3 | JAK1 2/4885JAK2 1/4885TYK2 5/4885 |
| US-20210340144-A1 | SMALL MOLECULE INHIBITORS OF THE JAK FAMILY OF KINASES | JAK2, JAK1, JAK3 | JAK1 2/4885JAK2 1/4885TYK2 5/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | JAK1 434/4885JAK2 122/4885TYK2 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.